| US 7,598,267 B2 | ||
| Muscarinic acetylcholine receptor antagonists | ||
| Dramane I. Laine, King of Prussia, Pa. (US); Brent W. McCleland, King of Prussia, Pa. (US); Christopher E. Neipp, King of Prussia, Pa. (US); and Michael R. Palovich, King of Prussia, Pa. (US) | ||
| Assigned to Glaxo Group Limited, Greenford, Middlesex (United Kingdom) | ||
| Appl. No. 11/568,930 PCT Filed May 10, 2005, PCT No. PCT/US2005/016148 § 371(c)(1), (2), (4) Date Nov. 10, 2006, PCT Pub. No. WO2005/112644, PCT Pub. Date Dec. 01, 2005. |
||
| Claims priority of provisional application 60/570581, filed on May 13, 2004. | ||
| Prior Publication US 2007/0173646 A1, Jul. 26, 2007 | ||
| Int. Cl. A01N 43/90 (2006.01); C07D 453/02 (2006.01) | ||
| U.S. Cl. 514—305 [546/133] | 42 Claims |
1. A compound of formula (I) as indicated below
 R1 is selected from hydrogen, C1-15 alkyl, halosubstituted C1-15 alkyl, aryl C1-15 alkyl, C1-15 alkyl cycloalkyl, cycloalkyl,
C2-15 alkenyl, hydroxy substituted C1-15 alkyl, C1-15 alkyl aryl, (CR7R7)qORa, (CR7R7)qNRaRa, (CR7R7)qNC(O)Ra, (CR7R7)qC(O)NRaRa,
(CR7R7)qC(O)Ra, (CR7R7)qC(O)ORa, or (CR7R7)qOC (O)Ra; or
R1 is:
 R2 and R3 are independently selected, from the group consisting of aryl, aryl C1-4 alkyl, C1-4 alkyl aryl, heteroaryl, heteroaryl
C1-4 alkyl, C1-4 alkyl heteroaryl, heterocyclic, C1-4 alkyl heterocyclic and a heterocyclic C1-4 alkyl moiety;
Ra is selected from the group consisting of hydrogen, C1-15 alkyl, C1-15 alkoxy, aryl, aryl C1-15 alkyl, heteroaryl, heteroaryl
C1-15 alkyl, heterocyclic and a heterocyclic C1-15 alkyl;
q is 0 or an integer having a value of 1 to 15;
n is an integer having a value of 1 to 14;
m is an integer having a value of 1 to 15;
p is an integer having a value of 1 to 4;
X, Y, Z and W are, independently, selected from the group consisting of hydrogen, C1-4 alkyl, C1-4 alkyl aryl, halosubstituted
C1-4 alkyl, and hydroxy substituted C1-4 alkyl;
V is selected from the group consisting of O, S, and NRb;
Rb is selected from the group consisting of hydrogen, C1-4 alkyl and aryl C1-4 alkyl;
R7 is selected from the group consisting of hydrogen, C1-4 alkyl, halosubstituted C1-4 alkyl, and hydroxy substituted C1-4
alkyl; and
X— is a physiologically acceptable anion.
|